Galapagos NV




Biotechnology & Medical Research

Market Closed - Euronext Amsterdam 11:38:45 2024-03-01 am EST 5-day change 1st Jan Change
32.3 EUR -1.79% Intraday chart for Galapagos NV -2.30% -12.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Galapagos to Seek Acquisitions CI
Transcript : Galapagos NV, 2023 Earnings Call, Feb 23, 2024
Frontier Medicines Corporation announced that it has received $80 million in funding from Deerfield Management Company, L.P. Series C, DROIA nv, Galapagos NV, DCVC, MPM Asset Management, L.L.C., RA Capital Management, L.P. and other investors CI
Galapagos NV Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024 CI
Galapagos Completes Sale of Jyseleca Business to Alfasigma MT
Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV. CI
Galapagos NV Enters into Strategic Collaboration Agreement with Thermo Fisher Scientific, Inc. to Further Expand Its Decentralized CAR-T Manufacturing Network in the U.S CI
Galapagos Partners with Thermo Fisher for Manufacturing in US MT
Galapagos, Thermo Fisher Scientific to Establish Decentralized CAR-T Manufacturing Network MT
Galapagos, Thermo Fisher to Collaborate on Expanding Manufacturing of Cancer Drug DJ
Galapagos, BridGene Biosciences Partner to Develop New Medicines for Oncology Targets MT
Galapagos to Collaborate With BridGene to Discover, Develop New Medicines for Oncology Targets MT
BridGene Biosciences, Inc. Announces Strategic Collaboration and Licensing Agreement with Galapagos NV CI
Global markets live: HSBC, Baidu, Exxon Mobil, Geely, Tesla... Our Logo
Galapagos to Divest Jyseleca Business in Biotechnology Shift MT
Michele Manto to Join Alfasigma and Resigns from His Position as Chief Commercial Officer and Executive Committee Member At Galapagos CI
Galapagos Announces Start of PAPILIO-1 Phase 1/2 Multiple Myeloma Study of Point-Of-Care Manufactured BCMA CAR-T Candidate, GLPG5301 CI
Galapagos Begins Clinical Trial for Cell Maturation Antigen on Patients with Refractory Multiple Myeloma MT
Galapagos Presents New Encouraging Clinical Data from the Ongoing Phase 1/2 CD19 CAR-T Studies with GLPG5201 and GLPG5101 CI
Transcript : Galapagos NV - Special Call
JPMorgan Cuts Galapagos Price Target to $37 From $45, Maintains Neutral Rating MT
Galapagos Signs Strategic Manufacturing Deal With Landmark Bio MT
Galapagos Nv Releases New Encouraging Data from Car-T Studies for Presentation At Ash 2023 CI
Transcript : Galapagos NV, Q3 2023 Earnings Call, Nov 03, 2023
Chart Galapagos NV
More charts
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
32.3 EUR
Average target price
39.53 EUR
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock Galapagos NV - Euronext Amsterdam
  4. News Galapagos NV
  5. Galapagos Signs Strategic Manufacturing Deal With Landmark Bio
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.